论文部分内容阅读
目的探讨来氟米特治疗免疫性血小板减少性紫癜的疗效和安全性。方法 6例血小板减少性紫癜患者口服来氟米特治疗,20 mg/d×3 d,以后10 mg/d,至血小板正常后4~12周停服来氟米特;记录治疗前后血小板变化、药物不良反应。结果治疗4周,3例血小板正常,5例血小板升高数>20×109/L。完成观察治疗12周4例,2例完全缓解,1例部分缓解,1例轻微缓解。1例出现轻微恶心症状,1例因白细胞减少退出,1例长期使用糖皮质激素者因肺部感染死亡。结论来氟米特适用于治疗免疫性血小板减少性紫癜患者,不良反应轻微,耐受性良好。
Objective To investigate the efficacy and safety of leflunomide in the treatment of immune thrombocytopenic purpura. Methods Six patients with thrombocytopenic purpura were treated with leflunomide 20 mg / d × 3 d for the following 10 mg / d until leflunomide 4 to 12 weeks after the platelets were normal. The changes of platelets before and after treatment were recorded. medical side effects. Results The treatment for 4 weeks, 3 cases of normal platelets, 5 cases of thrombocytopenia> 20 × 109 / L. After completion of observation and treatment of 12 cases in 4 cases, 2 patients completely relieved, 1 patient partially relieved, 1 patient slightly relieved. One patient had slight nausea, one patient with leukopenia and one patient with long-term glucocorticoids died from pulmonary infection. Conclusion Leflunomide is suitable for the treatment of patients with immune thrombocytopenic purpura with mild adverse reactions and good tolerability.